Scilex Holding Company Total Liabilities
Scilex Holding Company total liabilities. Based on the latest financial reports, Scilex Holding Company (SCLX) has total liabilities worth $564.05 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Scilex Holding Company liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Scilex Holding Company (2020–2025)
Total liabilities of Scilex Holding Company from 2020 to 2025. This chart illustrates how Scilex Holding Company's total liabilities have evolved over time, based on quarterly financial data. Explore long-term investment intensity of Scilex Holding Company to see how much of total assets are deployed in long-term investments.
Scilex Holding Company Competitors by Total Liabilities
The table below lists competitors of Scilex Holding Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stallion Uranium Corp.
V:STUD
|
Canada | CA$3.60 Million |
|
Dyadic International Inc
NASDAQ:DYAI
|
USA | $9.07 Million |
|
Moleculin Biotech Inc
NASDAQ:MBRX
|
USA | $7.12 Million |
|
Reborn Coffee Inc
NASDAQ:REBN
|
USA | $11.07 Million |
|
Nafpaktos Textile Industry S.A
AT:NAYP
|
Greece | €18.91 Million |
|
Imexhs Ltd
AU:IME
|
Australia | AU$8.36 Million |
|
INOVIQ LTD.
F:EGQ0
|
Germany | €1.72 Million |
|
Mico BioMed Co. Ltd.
KQ:214610
|
Korea | ₩7.88 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Scilex Holding Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SCLX total assets.
Liquidity & Leverage Metrics
Scilex Holding Company Total Liabilities Ratios Explained
Scilex Holding Company total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scilex Holding Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scilex Holding Company (2020–2025)
The table below shows the annual total liabilities of Scilex Holding Company from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $576.73 Million | +101.94% |
| 2024-12-31 | $285.59 Million | +4.14% |
| 2023-12-31 | $274.25 Million | +445.35% |
| 2022-12-31 | $50.29 Million | -83.34% |
| 2021-12-31 | $301.81 Million | +35.23% |
| 2020-12-31 | $223.19 Million | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more